Background/Aims: Circular RNAs (circRNAs) play a crucial role in the occurrence of several diseases, including autoimmune diseases. However, their role in primary biliary cholangitis (PBC) remains unclear. Here, we aimed to determine the circRNA expression profile in plasma from PBC patients and further explore the value of circRNA in diagnosing PBC. Methods: CircRNA microarrays were used to determine circRNA expression profiles in plasma samples from 6 PBC patients and 6 healthy controls. Statistical analyses identified differentially expressed circRNAs, and these circRNAs were verified by qRT-PCR in 29 PBC patients and 30 healthy controls. MicroRNA (miRNA) target prediction software identified putative miRNA response elements (MREs), which were used to construct a map of circRNA-miRNA interactions for the differentially expressed circRNAs. Results: Our results indicated that there were 18 up-regulated and 4 down-regulated circular RNAs in the plasma from PBC patients compared with that from healthy individuals. Among the differentially expressed circRNAs, hsa_circ_402458 (P=0.0033), hsa_circ_087631 and hsa_circ_406329 (P=0.0185) were up-regulated, and hsa_circ_407176 (P=0.0066) and hsa_circ_082319 were down-regulated in the PBC group versus the healthy group as demonstrated by qRT-PCR. In particular, hsa_circ_402458 was significantly higher in PBC patients not receiving UDCA treatment than in PBC patients receiving UDCA treatment (P=0.0338). The area under the receiver operating characteristic curve for hsa_circ_402458 for diagnosing PBC was 0.710 (P=0.005). For hsa_circ_402458, two putative miRNA targets, hsamiR-522-3p and hsa-miR-943, were predicted. Conclusions: circRNA dysregulation may play a role in PBC pathogenesis, and hsa_circ_402458 shows promise as a candidate biomarker for PBC.
Microarray Expression Profile of Circular RNAs in Plasma from Primary Biliary Cholangitis Patients
and gradual destruction of the small intrahepatic bile ducts, which leads to fibrosis; PBC may also lead to cirrhosis, which is caused by its resulting complications. PBC is mainly diagnosed in women, with a female to male ratio of approximately 10 to 1 [1, 2] . The pathogenesis of PBC is complex and involves genetic, environmental, autoimmune and other factors; its precise mechanism has not yet been fully elucidated. Ursodeoxycholic acid (UDCA) is the established first-line therapy and the current standard of care for PBC. However, up to 40% of patients have an incomplete biochemical response to UDCA, and this has been shown to be associated with the risk of progression to end-stage liver disease and worse transplantfree survival rates than those in UDCA-responsive patients [3] [4] [5] . PBC is usually hard to detect in asymptomatic patients until the disease progresses to a more severe stage; at the severe stage, serum liver function screening and UDCA therapy are commonly used. What is worse, most asymptomatic patients become symptomatic and may die or require a liver transplant within 5 years of not receiving an intervention [6, 7] . Overall survival rates in these asymptomatic patients are shorter than those predicted for age-and gender-matched control populations. The median survival is only 6~10 years [8] . At present, histological staging is used to confirm PBC diagnoses and stratification; however, an ideal non-invasive molecular marker for diagnosing PBC in its early stages, assessing its disease progression and determining treatment efficacy is lacking. Circular RNAs (circRNAs) are a novel type of universal and diverse endogenous noncoding RNA (ncRNA); unlike linear RNAs, they form covalently closed continuous loops and act as gene regulators in mammals [9] . CircRNAs are differentially generated by backsplicing exons or from lariat introns. The 3' and 5' ends normally present in an RNA molecule can be joined together by covalent bonds; this leads to circularization, resistance to RNA exonucleasemediated degradation, and high stability [10, 11] . Interestingly, circRNAs are abundant, evolutionally conserved and relatively stable in the cytoplasm; these properties indicate that circRNAs may be more suitable biomarkers than other types of RNA [12] . CircRNAs play important roles as miRNA sponges or interact with RNA-associated proteins to form RNAprotein complexes that regulate gene transcription [13, 14] . CircRNAs have been identified in exosomes, and more recently, chromosomal translocation in cancer has been shown to generate aberrant fusion-circRNAs associated with resistance to drug treatments [15, 16] . In addition, though they were originally thought to be non-coding, there is now increasing evidence to suggest that select circRNAs can be translated into functional proteins [17] . Although much remains to be elucidated regarding circRNA biology and their mechanisms of gene regulation, emerging evidence has revealed the function of circRNAs in various cancers [18] and other human diseases, such as cardiovascular disease, Alzheimer's disease, and diabetes [19] [20] [21] ; thus, circRNAs may potentially serve as novel biomarkers and therapeutic targets for treating such diseases.
In the present study, we identified a small number of circRNAs that are up-or downregulated in the plasma from PBC patients; these circRNAs may have important functions in PBC development and progression. Importantly, increased expression levels of hsa_ circ_402458 in plasma from PBC patients may serve as a sensitive and specific biomarker for diagnosing PBC patients.
Materials and Methods

Patients and Blood samples
The subjects studied herein were classified into two cohorts; the cohort for circRNA microarray analysis included 6 PBC patients and 6 healthy controls. The cohort for the real-time PCR analysis included 29 PBC patients and 30 healthy individuals. Diagnoses for all patients were based on the established criteria for PBC [3] . All individuals enrolled in this study were were subjected to serum liver function, autoimmune antibody and immunoglobulin assays and liver ultrasounds. HBsAg and anti-HCV were also tested to exclude the possibility of HBV and HCV infection. The clinical features of this cohort are presented in 
RNA extraction
For each sample, the total RNA from 2 mL of plasma containing EDTA anticoagulant was extracted by using TRIZOL reagent (Invitrogen, NY, USA) in accordance with the manufacturer's protocol; the total RNA was then quantified using a NanoDrop ND-1000 spectrophotometer (Thermo Fisher Scientific, Waltham, USA). The RNA integrity of each sample was assessed by denaturing agarose gel electrophoresis.
CircRNA microarray labelling and hybridization
RNA from the plasma of six PBC patients and six control subjects was extracted for microarray analysis; we pooled three samples together for the microarray assay to minimize patient heterogeneity. Total RNA from each sample was quantified using a NanoDrop ND-1000. Sample preparation and microarray hybridization were performed based on the standard protocol from Arraystar (Arraystar, Rockville, USA). Briefly, total RNA was digested with RNase R (Epicentre, Madison, USA) to remove linear RNAs and enrich circRNAs. Then, the enriched circRNAs were amplified and transcribed into fluorescent cRNA using a random priming method and an Arraystar Super RNA Labeling Kit (Arraystar, Rockville, USA). The labelled cRNAs were purified by using an RNeasy Mini Kit (Qiagen, Hilden, Germany). The concentration and specific activity of the labelled cRNAs (pmol Cy3/μg cRNA) were measured by a NanoDrop ND-1000. A total of 1 μg of each labelled cRNA was fragmented by adding 5 μl of 10× blocking agent and 1 μl of 25× fragmentation buffer; then, the mixture was heated at 60 °C for 30 min; finally 25 μl of 2× hybridization buffer was added to dilute the labelled cRNA. A total of 50 μl of hybridization solution was dispensed into the gasket slide and added to the Arraystar Human CircRNA Array V2.0 (8x15K) (Arraystar, Rockville, USA). The slides were incubated for 17 hours at 65°C in an Agilent Hybridization Oven. The hybridized arrays were washed, fixed and scanned using the Agilent Scanner G2505C.
CircRNA microarray data analysis
Scanned images were imported into Agilent Feature Extraction software (version 11.0.1.1) for raw data extraction. Quantile normalization of the raw data and subsequent data processing were performed using the R software package (R version 3.1.2). After quantile normalization of the raw data, low intensity filtering was performed, and circRNAs that had flags in "P" or "M" ("All Targets Value") for at least 3 out of 6 samples were retained for further analyses. CircRNAs that were differentially expressed between the two groups were conveniently estimated by fold-change filtering and Student's t-tests. CircRNAs with fold changes ≥ 1.5 and p-values ≤ 0.05 were selected as significantly differentially expressed.
Real-time PCR Analysis
cDNA samples were prepared from 3.0 μg of total RNA by reverse transcription using a Maxima First Strand cDNA Synthesis Kit (Fermentas, Hanover, USA) according to the supplier's instructions. In total, 8 candidate circRNAs were analysed by SYBR green I dye-based detection (Roche, Mannheim, Germany) with specific primer sequences ( Table 2 ). The PCR conditions for candidate circRNAs and reference genes were 5 
Statistical analysis
The results are reported as the mean ± SEM. All experiments were performed and analysed in triplicate. The results from two groups were evaluated using unpaired t-tests. The clinical diagnostic value of a given circRNA was verified by ROC curve analysis, and when the AUC was equal to 0.5, the circRNA was defined as having no diagnostic value. P<0.05 was considered statistically significant. All statistical analyses were conducted using GraphPad Prism V5.0 software (GraphPad Software, San Diego, USA).
Results
CircRNA expression profiles in peripheral blood from PBC patients
Hierarchical clustering was used to determine circRNA expression in PBC patients and healthy individuals (Fig. 1A) . Scatter and volcano plots show the variations in circRNA expression between the PBC patients and healthy individuals (Fig. 1B, C) . A total of 7344 circRNAs were detected by the Arraystar Human CircRNA Microarray. We identified 22 circRNAs that were differentially expressed in the PBC patients versus the healthy controls. Eighteen of these circRNAs were up-regulated (Table 3) , and 4 were down-regulated in the PBC patient plasma samples (Table 3) . Among the up-regulated circRNAs, 13 were exonic, 3 were intronic, and 1 was antisense. All the down-regulated circRNAs were exonic. Screening criteria were utilized to obtain candidate biomarkers that would be most applicable in 
clinical practice: the fold changes were ≥ 1.5, the P-values were ≤ 0.05, and the raw intensity values were ≥ 200 for each sample. 8 circRNAs (hsa_circ_402458, hsa_circ_052372, hsa_ circ_407176, hsa_circ_087631, hsa_circ_102485, hsa_circ_082319, hsa_circ_000361 and hsa_circ_406329) met these standards and were selected for subsequent verification by qRT-PCR.
Expression profiles of circRNAs verified by qRT-PCR
To validate the circRNA microarray results, qRT-PCR was performed to analyse selected circRNAs. Although hsa_circ_102845 was not successfully amplified, the other 7 circRNAs showed consistent results between the qPCR and microarray analyses ( Table 4, Table 3 ). All 
the selected circRNAs exhibited significantly higher expression levels in the PBC patients than in the healthy individuals (Table 4) . Five circRNAs, including hsa_circ_402458, hsa_ circ_407176, hsa_circ_087631, hsa_circ_082319 and hsa_circ_406329, were selected as candidate biomarkers for further validation in a large cohort. The expression levels of hsa_ circ_402458 (P=0.0033) and hsa_circ_406329 (P=0.0185) were significantly higher in the PBC group than in the healthy group; these results were consistent with the microarray data (Fig. 2) . Hsa_circ_407176 (P=0.0066) and hsa_circ_082319 had lower expression levels in the PBC group than in the healthy group; these expression patterns were opposite of the microarray data in the large validation cohort (Fig. 2 ). There were no significant differences in the expression levels of has_circ_087631 between the PBC patients and healthy controls (Fig. 2) . Moreover, we analysed the circRNA expression profiles in different groups according to different clinical characteristics (Fig. 3) . We determined that hsa_circ_402458 expression levels were significantly higher in PBC patients without UDCA treatment than in PBC patients receiving UDCA treatment (P=0.0338). There were no obvious differences in expression levels in PBC patients with cirrhosis vs. asymptomatic or UDCA responders vs. non-responders. There were no significant differences in has_circ_407176 and hsa_circ_406329 expression levels among the three subgroups. Taken together, hsa_circ_402458 expression levels were significantly higher in PBC patients not receiving UDCA therapy than in patients receiving UDCA. Expression levels of hsa_circ_402458, hsa_circ_407176, and hsa_circ_406329 in the three groups of PBC patients: patients not receiving UDCA therapy (n=5) and patients receiving UDCA therapy (n=24); UDCA non-responders (n=12) and UDCA responders (n=12); and patients with cirrhotic PBC (n=11) and patients with asymptomatic PBC (n=18). ΔCt values were used to measure gene expression, which was normalized to β-actin expression levels. The values presented are the means±SEM. **P<0.01. 
ROC curve analysis of differentially expressed circRNAs
The most significant differences in expression levels between the PBC and healthy groups were for hsa_circ_402458 (P=0.0033), hsa_circ_407176 (P=0.0066), and hsa_circ_406329 (P=0.0185). These 3 circRNAs were subjected to ROC curve analyses to determine their diagnostic values for PBC (Fig. 4, Table 5 ). The AUC of hsa_circ_402458 for diagnosing PBC was 0. Table 5 . From the 3 groups of data, hsa_circ_402458 was chosen as the best performing PBC biomarker due to its higher AUC, lower P value and higher expression levels.
Discussion
Primary biliary cholangitis (PBC) is a chronic inflammatory autoimmune disease that develops based on interactions between genetic and environmental factors. The first FDAapproved treatment for PBC was UDCA. Approximatively 30-40% of patients fail to respond to UDCA [22] . PBC is usually hard to detect in asymptomatic patients; they rarely visit hospitals to seek diagnosis and therapy until the disease has progressed to a more severe stage. What is worse, most asymptomatic patients become symptomatic and die or require a liver transplant within 5 years of not receiving the standard treatment [6, 7] .
Current diagnosis methods for PBC are mainly based on the clinical manifestations, serum biochemical features, and histopathological characteristics of patients. Liver histology characterized by non-suppurative cholangitis and the granulomatous destruction of interlobular bile ducts is one of the objective criteria for confirming PBC diagnosis and stratification [23] . In addition, serum antibodies specific for PBC are the other pivotal biomarkers for making a PBC diagnosis. It is well known that AMAs, especially AMA-M2, are excellent markers with high specificity and sensitivity for the routine diagnosis of PBC [24] . AMAs are present in 95% of PBC patients; however, 5% of patients with PBC are AMAnegative [25] . Notably, AMA-negative PBC patients had an observably worse prognosis than AMA-positive PBC patients [25] . AMA-negative PBC patients had observably lower free survival rates for liver-associated complications, including liver transplant and death, than AMA-positive PBC patients [25] . However, AMAs are not ideal haematological molecular markers for diagnosing PBC early, assessing its disease progression and determining treatment efficacy, especially for those AMA-negative PBC patients.
As a new class of non-coding RNAs, circular RNAs have attracted increasing attention from researchers. They may play an important role in gene expression and signalling pathways and participate in the development of human diseases [9, [26] [27] [28] . So far, there are few studies about the roles of circRNA in the pathogenesis of autoimmune diseases. Given the roles of miRNAs in the initiation and progression of autoimmune diseases and the roles of circRNAs in sponging miRNA and gene regulation, circRNAs may be associated with autoimmune disease initiation and progression and may be potential therapeutic targets for treatment. Only a few reports have reported dysregulated circRNA profiles in systemic lupus erythaematosus (SLE), multiple sclerosis (MS) and rheumatoid arthritis (RA), and certain circRNAs may serve as potential biomarkers for making a disease diagnosis [29] [30] [31] [32] . For PBC, some long noncoding RNAs (lncRNAs) and miRNAs have been demonstrated to be involved in the occurrence and development of PBC and can be used as biomarkers for identifying PBC patients [33] . However, circRNAs have two significant properties: they are highly conserved and remarkably stable with a half-life > 48 h. In addition to these properties, circRNAs can exist in exosomes and blood plasma because of their stability [9, 28] . Consequently, circRNAs may be superior to miRNAs and lncRNAs regarding the diagnosis of human disease and could be applied to PBC.
To the best of our knowledge, this study is the first to investigate the expression profiles of circRNAs in peripheral plasma from PBC patients and to improve the understanding of the role of circRNAs in the pathogenesis of PBC. From the microarray analysis, we identified 22 significantly differentially expressed circRNAs-18 up-regulated and 4 down-regulated circRNAs in PBC patients versus healthy controls. We then choose 8 circRNAs according to the established criteria and validated them by qRT-PCR in a larger cohort. Hsa_circ_402458 showed the greatest significant difference in expression and the highest diagnostic value for PBC among the candidate biomarkers, suggesting that hsa_circ_402458 can be considered a promising diagnostic biomarker for PBC in clinical practice and that it may be comparable with traditional serum biomarkers. What is more, hsa_circ_402458 is expressed at significantly higher levels in PBC patients not receiving any drug therapy than in PBC patients receiving UDCA therapy, suggesting that hsa_circ_402458 may participate in the pathogenesis of PBC.
The field of circRNAs is quite new, and to the best of our knowledge, no studies have definitively demonstrated the bio-function of hsa_circ_402458. Recently, it was reported that circRNAs function as miRNA 'sponges' that naturally sequester and competitively suppress miRNA activity. Their interaction with disease-associated miRNAs indicates that circular RNAs are important for regulating diseases [13] . To determine the function of candidate biomarker circRNAs, we searched for potential miRNA targets of circRNA utilizing Detailed annotation for hsa_circ_402458 and its potential miRNA target interactions. CircRNA/ microRNA interactions were predicted with miRNA target prediction software based on TargetScan [37] and miRanda [38] . Arraystar's miRNA target prediction software. For hsa_circ_402458, two putative miRNAs targets, hsa-miR-522-3p and hsa-miR-943, were selected (Fig. 5) . We speculated that hsa_ circ_402458 may target hsa-miR-522-3p and hsa-miR-943 and thus competitively suppress miRNA activity to participate in the pathogenesis of PBC. A previous study has demonstrated that miR-522-3p may be involved in the abnormal resolution of inflammation and may be a target for modulating chronic inflammatory disorders. Importantly, inflammation that is not resolved is a major driver of autoimmune diseases [34] . In addition, miR-943 was reported to be involved in the repair of DNA double-strand breaks through the TGF-beta signalling pathway. However, aberrant TGF-β1 signalling contributed to the development of PBC in a murine model [35, 36] . Therefore, we hypothesize that hsa_circ_402458 may function as a miRNA sponge and participate in the pathogenesis of PBC by influencing inflammationrelated signalling pathways. However, the potential function of these miRNA-circRNA axes in the pathogenesis of PBC requires further study. Taken together, our study compared the expression profiles of circRNAs in plasma from PBC patients and matched control subjects by microarray analysis; then, we confirmed our findings in another larger case-control cohort. The results demonstrated that hsa_ circ_402458 is a sensitive and specific biomarker for diagnosing PBC and may be involved in the pathogenesis of PBC via interacting with target miRNAs. The precise molecular mechanisms underlying circRNA functions in PBC still require further investigation.
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